NEW YORK, March 24, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
CVS Caremark Corporation (NYSE: CVS), Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA), Zoetis, Inc. (NYSE: ZTS), McKesson
Corporation (NYSE: MCK), and Mylan, Inc. (NASDAQ: MYL). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
CVS Caremark Corporation Analyst Notes
On March 18, 2014, CVS Caremark
Corporation (CVS Caremark) announced that its retail division
CVS/pharmacy is now providing ScripTalk talking prescription labels
for prescriptions ordered for home delivery through the Company's
online pharmacy - CVS.com - available to the blind or visually
impaired. The Company noted that ScripTalk is collaboration between
CVS/pharmacy, the American Foundation for the Blind, American
Council of the Blind, and California Council of the Blind. "The
California Council of the Blind applauds CVS's willingness to offer
access to the information on prescription medication labels. As a
result of this initiative, persons who are blind or visually
impaired who use CVS mail order to fill their prescription needs
will have the same direct, and independent access to label
information as do sighted customers," said Donna Pomerantz, President of California Council
of the Blind. The full analyst notes on CVS Caremark Corporation
are available to download free of charge at:
http://www.AnalystsReview.com/03242014/CVS/report.pdf
--
Teva Pharmaceutical Industries Ltd. Analyst Notes
On March 13, 2014, Teva
Pharmaceutical Industries Ltd. (Teva) announced collaboration with
the UK Government's National Health Service National Institute for
Health Research (NIHR) Office for Clinical Research Infrastructure
(NOCRI). The Company informed that the two-part collaboration,
Clinical Drug Development Collaboration and Dementia Research
Collaboration, follows the creation of an important new research
infrastructure model by the UK's National Health Service (NHS). "We
are delighted to collaborate with NIHR on both clinical development
and early dementia research. It will be a catalyst for innovation
to take place within a healthcare system that is admired the world
over," said Dr. Michael Hayden,
President of Global R&D and Chief Scientific Officer at Teva.
"The relationship between Teva, Israel and the UK is a long and fruitful one
and I am proud that we can now add another example of us working
together as partners for innovation and health." The full analyst
notes on Teva Pharmaceutical Industries Ltd. are available to
download free of charge at:
http://www.AnalystsReview.com/03242014/TEVA/report.pdf
--
Zoetis, Inc. Analyst Notes
On March 13, 2014, Zoetis, Inc.
(Zoetis) announced that it will participate in the Jefferies Animal
Health Summit. The Company's CEO Juan Ramón Alaix is scheduled to
present on March 27, 2014, at
9:30 a.m.ET at the Jefferies
Conference Center in New York, NY.
The full analyst notes on Zoetis, Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03242014/ZTS/report.pdf
--
McKesson Corporation Analyst Notes
On March 5, 2014, McKesson
Corporation (McKesson) announced that its Board of Directors has
elected N. Anthony Coles, M.D., as a
new independent director, effective April
29, 2014. Further, the Company informed that Dr. Coles has
also been appointed as a member of the Board's Compensation
Committee as well as the Finance Committee. His term as a director
will expire at McKesson's 2014 Annual Meeting of Stockholders
unless he is nominated again as a director, and elected by
stockholders at the meeting. The full analyst notes on McKesson
Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03242014/MCK/report.pdf
--
Mylan, Inc. Analyst Notes
On March 11, 2014, Mylan, Inc.
(Mylan) announced that it has launched Naloxone Hydrochloride
Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. The
Company noted that the product was determined to be bioequivalent
and therapeutically equivalent to the reference listed drug,
Naloxone Hydrochloride Injection 0.4 mg/mL of Hospira Inc. Mylan
further confirmed that the product's Abbreviated New Drug
Application (ANDA) has received final approval from the FDA. The
full analyst notes on Mylan, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03242014/MYL/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review